DK0839196T3 - Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner - Google Patents
Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteinerInfo
- Publication number
- DK0839196T3 DK0839196T3 DK96927237T DK96927237T DK0839196T3 DK 0839196 T3 DK0839196 T3 DK 0839196T3 DK 96927237 T DK96927237 T DK 96927237T DK 96927237 T DK96927237 T DK 96927237T DK 0839196 T3 DK0839196 T3 DK 0839196T3
- Authority
- DK
- Denmark
- Prior art keywords
- ctla
- acid sequence
- amino acid
- seq
- related proteins
- Prior art date
Links
- 108050003558 Interleukin-17 Proteins 0.000 title abstract 2
- 102000013691 Interleukin-17 Human genes 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50403295A | 1995-07-19 | 1995-07-19 | |
| US08/514,014 US5707829A (en) | 1995-08-11 | 1995-08-11 | DNA sequences and secreted proteins encoded thereby |
| PCT/US1996/011889 WO1997004097A2 (en) | 1995-07-19 | 1996-07-18 | Human ctla-8 and uses of ctla-8-related proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0839196T3 true DK0839196T3 (da) | 2005-09-12 |
Family
ID=27054704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96927237T DK0839196T3 (da) | 1995-07-19 | 1996-07-18 | Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP0839196B1 (da) |
| JP (3) | JPH11510045A (da) |
| AT (1) | ATE295414T1 (da) |
| AU (1) | AU727480B2 (da) |
| CA (1) | CA2227220A1 (da) |
| DE (1) | DE69634726T2 (da) |
| DK (1) | DK0839196T3 (da) |
| ES (1) | ES2242966T3 (da) |
| PT (1) | PT839196E (da) |
| WO (1) | WO1997004097A2 (da) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274711B1 (en) | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| EP1352962A1 (en) * | 1997-03-07 | 2003-10-15 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| WO1998039448A2 (en) * | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| WO1999066041A1 (en) * | 1998-06-16 | 1999-12-23 | Human Genome Sciences, Inc. | 94 human secreted proteins |
| US6878687B1 (en) | 1997-03-07 | 2005-04-12 | Human Genome Sciences, Inc. | Protein HMAAD57 |
| WO1998039446A2 (en) * | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 70 human secreted proteins |
| US7053190B2 (en) | 1997-03-07 | 2006-05-30 | Human Genome Sciences, Inc. | Secreted protein HRGDF73 |
| US6420526B1 (en) | 1997-03-07 | 2002-07-16 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| JP2001522239A (ja) * | 1997-03-21 | 2001-11-13 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | ８７個のヒト分泌タンパク質 |
| AU6891098A (en) * | 1997-04-10 | 1998-10-30 | Genetics Institute Inc. | Secreted expressed sequence tags (sests) |
| AU6956798A (en) * | 1997-04-10 | 1998-10-30 | Genetics Institute Inc. | Secreted expressed sequence tags (sests) |
| EP0973898A2 (en) * | 1997-04-10 | 2000-01-26 | Genetics Institute, Inc. | SECRETED EXPRESSED SEQUENCE TAGS (sESTs) |
| CA2291260A1 (en) * | 1997-06-06 | 1998-12-10 | Human Genome Sciences, Inc. | 207 human secreted proteins |
| EP1428833A3 (en) * | 1997-06-06 | 2004-07-07 | Human Genome Sciences, Inc. | 207 human secreted proteins |
| US6548633B1 (en) | 1998-12-22 | 2003-04-15 | Genset, S.A. | Complementary DNA's encoding proteins with signal peptides |
| US6562578B1 (en) | 1999-01-11 | 2003-05-13 | Schering Corporation | IL-17-like cytokine binding compounds and antibodies |
| CA2321970A1 (en) | 1998-02-26 | 1999-09-02 | Human Genome Sciences, Inc. | 36 human secreted proteins |
| US7223727B2 (en) | 1998-04-09 | 2007-05-29 | Serono Genetics Institute S.A. | GSSP4 polynucleotides and polypeptides and uses thereof |
| US7060479B2 (en) | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
| US6251583B1 (en) | 1998-04-27 | 2001-06-26 | Schering Corporation | Peptide substrates for HCV NS3 protease assays |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| NZ508878A (en) | 1998-05-15 | 2003-08-29 | Genentech Inc | IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells |
| CA2329274A1 (en) * | 1998-05-29 | 1999-12-02 | Steven M. Ruben | Interleukin-21 |
| CA2333917A1 (en) * | 1998-07-15 | 2000-01-27 | Human Genome Sciences, Inc. | 71 human secreted proteins |
| US7091315B1 (en) | 1998-07-15 | 2006-08-15 | Human Genome Sciences, Inc. | Protein HDPBQ71 |
| DK1114156T3 (da) * | 1998-09-17 | 2008-03-03 | Zymogenetics Inc | Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr |
| DE60043051D1 (de) * | 1999-01-11 | 2009-11-12 | Schering Corp | Dafür kodierende polynukleotide. verwendungen |
| CA2296792A1 (en) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| EP1053751A1 (en) * | 1999-05-17 | 2000-11-22 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compositions and methods for treating cell proliferation disorders |
| JP5583308B2 (ja) * | 1999-11-12 | 2014-09-03 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ２１個のヒト分泌タンパク質 |
| WO2001042451A2 (en) | 1999-12-08 | 2001-06-14 | Genset | FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS |
| EP1259253A2 (en) * | 2000-02-29 | 2002-11-27 | ZymoGenetics, Inc. | Methods for promoting production of myelin by schwann cells |
| US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
| EP2389943A1 (en) * | 2000-04-18 | 2011-11-30 | Schering Corporation | Use of IL-174 antagonists for treating Th2-related diseases |
| US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CN1329090A (zh) * | 2000-06-21 | 2002-01-02 | 上海博德基因开发有限公司 | 一种新的多肽——人自身免疫疾病相关蛋白10和编码这种多肽的多核苷酸 |
| AU2002246746B2 (en) | 2000-10-18 | 2007-05-31 | Kirin-Amgen, Inc. | Methods for treating rheumatoid arthritis using il-17 antagonists |
| US20050089957A1 (en) * | 2001-10-19 | 2005-04-28 | Audrey Goddard | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| EP1572116A4 (en) * | 2002-11-26 | 2007-12-12 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| PL2784084T5 (pl) | 2003-07-08 | 2024-12-02 | Novartis Pharma Ag | Przeciwciała antagonistyczne heterologicznych polipeptydów il-17a/f |
| US20070269428A1 (en) | 2003-11-21 | 2007-11-22 | Celltech R&D Limited | Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity |
| GB0417487D0 (en) * | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| US20070218065A1 (en) | 2006-03-10 | 2007-09-20 | Jaspers Stephen R | Antibodies that bind both il-17a and il-17f and methods of using the same |
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP2150564A2 (en) | 2007-04-27 | 2010-02-10 | ZymoGenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
| SG10201608871XA (en) | 2008-05-05 | 2016-12-29 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| CA2759848C (en) | 2009-05-05 | 2018-12-04 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
| EP2432493A1 (en) * | 2009-05-20 | 2012-03-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of il-17 polypeptides for use in the prevention or treatment of atherosclerosis |
| HRP20171939T1 (hr) | 2010-01-15 | 2018-03-23 | Kirin-Amgen, Inc. | Formulacija protutijela i režimi terapije |
| SG10201510762YA (en) | 2011-01-14 | 2016-01-28 | Ucb Pharma Sa | Antibody molecules which bind il-17a and il-17f |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562333B1 (en) * | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
| NZ306653A (en) * | 1995-03-23 | 1999-03-29 | Immunex Corp | Isolated dna il-17 receptors |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
-
1996
- 1996-07-18 EP EP96927237A patent/EP0839196B1/en not_active Expired - Lifetime
- 1996-07-18 CA CA002227220A patent/CA2227220A1/en not_active Abandoned
- 1996-07-18 ES ES96927237T patent/ES2242966T3/es not_active Expired - Lifetime
- 1996-07-18 WO PCT/US1996/011889 patent/WO1997004097A2/en not_active Ceased
- 1996-07-18 AU AU67123/96A patent/AU727480B2/en not_active Ceased
- 1996-07-18 DE DE69634726T patent/DE69634726T2/de not_active Expired - Lifetime
- 1996-07-18 DK DK96927237T patent/DK0839196T3/da active
- 1996-07-18 AT AT96927237T patent/ATE295414T1/de not_active IP Right Cessation
- 1996-07-18 EP EP05009086A patent/EP1591529A3/en not_active Withdrawn
- 1996-07-18 JP JP9506846A patent/JPH11510045A/ja not_active Withdrawn
- 1996-07-18 PT PT96927237T patent/PT839196E/pt unknown
-
2007
- 2007-11-21 JP JP2007301924A patent/JP4319686B2/ja not_active Expired - Fee Related
-
2009
- 2009-04-02 JP JP2009090326A patent/JP2009197000A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69634726T2 (de) | 2006-05-04 |
| JP4319686B2 (ja) | 2009-08-26 |
| JP2008131942A (ja) | 2008-06-12 |
| ES2242966T3 (es) | 2005-11-16 |
| AU6712396A (en) | 1997-02-18 |
| EP1591529A2 (en) | 2005-11-02 |
| EP1591529A3 (en) | 2005-11-09 |
| ATE295414T1 (de) | 2005-05-15 |
| EP0839196A2 (en) | 1998-05-06 |
| PT839196E (pt) | 2005-09-30 |
| CA2227220A1 (en) | 1997-02-06 |
| JPH11510045A (ja) | 1999-09-07 |
| DE69634726D1 (de) | 2005-06-16 |
| WO1997004097A3 (en) | 1997-09-12 |
| MX9800507A (es) | 1998-05-31 |
| EP0839196B1 (en) | 2005-05-11 |
| AU727480B2 (en) | 2000-12-14 |
| JP2009197000A (ja) | 2009-09-03 |
| WO1997004097A2 (en) | 1997-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0839196T3 (da) | Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner | |
| NO20074516L (no) | Pattedyrcytokinlignende polypeptid-1 | |
| ATE536406T1 (de) | Neuartiger zytokin-zcytor17-ligand | |
| DK35593D0 (da) | Polypeptid kodet af lav-dna-sekvens | |
| DK150992A (da) | Fremgangsmaade til fremstilling af et polypeptidfragment af faktor viii:c, dna-sekvens og ekstrachromosomalt element indeholdende en saadan dna-sekvens, som koder herfor | |
| DE3770915D1 (de) | Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli. | |
| ATE378408T1 (de) | Transformierender wachstumsfaktor beta-9 (ztgfss9) aus säugetieren | |
| DK1908772T3 (da) | Polypeptider og polynucleinsyrer af phorphorymonas gingivalis | |
| ATE482272T1 (de) | Zytokinproteinfamilie | |
| NO882380D0 (no) | Fibfonektin-bindende protein, samt fremstilling derav. | |
| DK0728208T3 (da) | Tomat-xyloglucan-endo-transglycosylase | |
| DK0580672T3 (da) | Syntetisk CDw52-(CAMPATH-1)-peptidantigen | |
| CY1111763T1 (el) | ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51 | |
| DE59108261D1 (de) | Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung | |
| ATE432985T1 (de) | Polypeptide mit aktivität der stimulierung von neutrophilen | |
| TH30275A (th) | โปรตีนดัดแปลง |